BridgeBio Pharma, Inc. entered into a Funding Agreement with LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S. r.l. for a $500 million investment upon FDA approval of acoramidis, with the Purchasers receiving 5% of global Net Sal...